RecruitingNot ApplicableNCT04923984
Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)
Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada -EMMA-Can
Sponsor
University of Manitoba
Enrollment
1,000 participants
Start Date
May 1, 2021
Study Type
INTERVENTIONAL
Conditions
Summary
EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.
Eligibility
Min Age: 18 Years
Inclusion Criteria1
- \- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.
Exclusion Criteria2
- If informed consent cannot be obtained from the patient or their substitute decision maker.
- Known allergy to liquid embolic agent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREEmbolization of the middle meningeal artery
embolization of the middle meningeal artery with an embolic agent (Microparticles, liquid embolic agents, SwiftPAC coils or others).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04923984
Related Trials
Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH) (HARMONY)
NCT072580697 locations
Neurosurgical Outcome Network
NCT0672402927 locations
Scalp Block Versus General Anesthesia in Patients Undergoing Evacuation of Subdural Hematoma Via Burr Hole
NCT071437991 location